Glycoprotein Ib-von Willebrand Factor Interactions Activate Tyrosine Kinases in Human Platelets

By Naoki Asazuma, Yukio Ozaki, Kaneo Satoh, Yutaka Yatomi, Makoto Handa, Yoshihiro Fujimura, Shuji Miura, and Shoji Kume

THROMBUS FORMATION is initiated by platelet adhesion to the sites of vascular injuries. The sequence of these processes involves the exposure of subendothelial extracellular matrices and the interaction between von Willebrand factor (vWF) and a platelet membrane receptor, glycoprotein Ib (GPIb). Human vWF serves to bridge the constituents of subendothelium to GPIb on the membrane of circulating platelets. The role of the vWF-GPIb interaction in platelet activation is particularly important when the hemodynamic condition creates high shear stress at the sites of arterial occlusion. Whereas much is known about the molecular bases of the interaction between vWF and GPIb, little has been clarified about the intracellular signal transduction pathway in platelet activation induced by the vWF-GPIb interaction. The role of intracellular Ca\(^{2+}\) elevation as a secondary mediator has been suggested for the ristocetin-induced GPIb-vWF interaction and shear-induced platelet aggregation.\(^{5,7}\) Protein kinase C activation also occurs in GPIb-mediated platelet activation.\(^{9}\) However, as shown for other cells, these two signal transduction pathways cannot totally explain the activation mechanism involved in the vWF-GPIb interaction.

Recently, an accumulating body of evidence has suggested that protein tyrosine phosphorylation plays an important role in intracellular signal transduction, especially in cell growth, cell-cell, and cell-matrix adhesive interactions. Platelets contain high activity of tyrosine kinases. All platelet tyrosine kinases reported to date are nonreceptor types, with p60\(^c-src\) being the most abundant.\(^{10}\) In addition to p60\(^c-src\), several tyrosine kinases have been identified, such as p54/58\(^lyn\), p59\(^fyn\), and p62\(^yes\), which are related to the src family, and other structurally unrelated kinases such as p72\(^syk\) and p125\(^FAK\).\(^{11,12}\) Various agonists induce the appearance of a number of tyrosine-phosphorylated proteins, and activation of p72\(^syk\), p60\(^c-src\), and p125\(^FAK\) occurs with distinct time courses. p72\(^syk\) activation occurs immediately after platelet activation, whereas p125\(^FAK\) is only activated when platelets are highly aggregated.\(^{13}\) A wide range of platelet functions, including intracellular Ca\(^{2+}\) mobilization and GPIIb/IIIa activation, appear to be regulated by tyrosine kinase activity. These lines of evidence suggest that protein-tyrosine phosphorylation and tyrosine kinase activation are closely related to the regulation of platelet function, ranging from the initial phase of activation to the late stage of aggregation.

On the other hand, there have been only a few reports on the involvement of protein-tyrosine phosphorylation in the GPIb-vWF interaction. Platelet activation mediated by the vWF-GPIb interaction resulted in protein-tyrosine phosphorylation of a 64-kD protein.\(^{14}\) Razdan et al\(^{15}\) and Oda et al\(^{16}\) have shown that shear stress causes a time-dependent appearance of tyrosine-phosphorylated proteins in human platelets. p60\(^c-src\) translocates to cytoskeleton upon platelet activation induced by the GPIb-vWF interaction.\(^{17}\) However, to the best of our knowledge, there has been no report on the identification of specific tyrosine-phosphorylated proteins or the activation of a specific tyrosine kinase(s) induced by the vWF-GPIb interaction. In a preliminary study, we found that ristocetin, a widely used agent for facilitating the vWF-GPIb interaction, nonspecifically interferes with tyrosine kinase activity. This adverse effect of ristocetin on tyrosine kinases may be a factor that has precluded the evaluation of tyrosine kinase activity in platelet activation induced by the vWF-GPIb interaction. To circumvent this hindrance, we evaluated the effects of a GPIb-interacting agent, botrocetin. Botrocetin, purified from the Bothrops jararaca venom, induces platelet agglutination by facilitating the binding of vWF-GPIb interaction. These findings suggest that the excessive presence of inhibitory anti-GPIb MoAb dissociated a kinase activity from GPIb. Phosphoamino acid analysis showed that the kinase activity was that of a tyrosine kinase. The identity of the tyrosine kinase and the mode of interaction with the cytoplasmic region of GPIb await to be determined. Our findings suggest that the tyrosine kinase associated with GPIb serves at a most proximal step in the signal transduction pathway involved in the vWF-GPIb-induced platelet activation, which leads to other tyrosine kinase-related intracellular signals.

From the Department of Clinical and Laboratory Medicine, Yamashiki Medical University, Tamahiro, Nakakoma, Yamashiki, Japan; the Blood Center, Keio University, Shinjuku, Tokyo, Japan; and the Department of Blood Transfusion, Nara Medical University, Kashihara, Nara, Japan.

Submitted February 19, 1997; accepted August 5, 1997.

Address reprint requests to Yukio Ozaki, MD, Department of Clinical and Laboratory Medicine, Yamashiki Medical University, Shimokato 1110, Tamahiro, Nakakoma, Yamashiki 609-38, Japan.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology.


4789
vWF to GPIb, similar to ristocetin, and the site of action at the vWF molecule has also been determined.

In the present study, we present several lines of evidence to suggest that tyrosine kinases are involved in the GPIb-vWF–induced intracellular signals and that a tyrosine kinase activity associates with GPIb upon the vWF-GPIb interaction, which can be immunoprecipitated with nonfunctional anti-GPIb MoAbs, but not by inhibitory anti-GPIb MoAbs.

**MATERIALS AND METHODS**

**Materials.** Monoclonal antibodies (MoAbs) against p72 lyn , p54/58, and leupeptin were obtained from Wako Pure Chemical Industries, Ltd (Tokyo, Japan). Anti-p60 src MoAb (GD11), anti-phosphotyrosine MoAb (4G10), and anti-p42/44 Erk MoAb were purchased from Upstate Biotechnology, Inc (Lake Placid, NY). Gly-Agr-Gly-Asp-Ser (GRGDS) peptide was obtained from Peptide Institute (Osaka, Japan). Anti-Shc polyclonal Ab was obtained from Transduction Laboratories (Lexington, KY). Acetyl salicylic acid, enolase, bovine serum albumin (BSA), prostaglandin I₂ (PGI₂), phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate, and Triton X-100 were from Sigma (St Louis, MO). Protein A-Sepharose was obtained from Pharmacia Japan (Tokyo, Japan). Peroxidase-conjugated goat antimouse Ig (IgG) was from Cappel Organ Teknika Co (Durham, NC). vWF was purified as previously described. The crude venom of Bothrops jararaca was purchased from Sigma, and the “two-chain” botrocetin and jararaca GPIb–BP were highly purified, based on the method of Fujimura et al. A nonfunctional anti-GPIb MoAb, WGA-3, and an inhibitory anti-GPIb MoAb, GUR33-35, which interferes with the binding of vWF to GPIb, were provided from Dr M. Handa (Keio University, Tokyo, Japan). Both antibodies reacted with the NH₂-terminal 45-kD trypsin fragment of GPIbα subunit as determined by the previously described method using solid-phase immunoisolation technique. Another nonfunctional anti-GPIb MoAb, GS-70, which also reacts with GPIbα (unpublished data), was a generous gift from Dr N. Yamamoto (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan). NKYS5-5, an anti-GPIb MoAb that inhibits the binding of vWF to GPIb, was provided by Dr S. Nomura (Kansai Medical University, Osaka, Japan).

**Platelet preparation.** Venous blood from healthy drug-free volunteers was collected into a tube containing acid-citrate-dextrose. Platelet-rich plasma obtained after centrifugation of whole blood at 160g for 10 minutes was incubated with 1 mmol/L acetylsalicylic acid (ASA) for 30 minutes to exclude the secondary effects of thromboxane A₂ (TXA₂), unless otherwise stated. The platelets were washed and resuspended in HEPES buffer containing 138 mmol/L NaCl, 3.3 mmol/L NaH₂PO₄, 2.9 mmol/L KCl, 1.0 mmol/L MgCl₂, 1 mg/mL of glucose, and 20 mmol/L HEPES (pH 7.4) at a concentration of 10⁷ cells/mL. Thirty minutes before experiments were performed, the platelet suspension was supplemented with 1 mmol/L CaCl₂, unless otherwise stated.

**Platelet aggregation.** Washed platelets were activated with 10 μg/mL of wvF and 3 μg/mL of botrocetin under continuous stirring at 1,000 rpm for the indicated periods in an AA-100 platelet aggregation analyzer (Sysmex, Kobe, Japan). The instrument was calibrated with a platelet suspension for zero light transmission and with buffer for 100% transmission.

**Identification of phosphotyrosine-containing proteins by immunoblotting.** After platelet activation, reactions were terminated by adding Laemmli sodium dodecyl sulfate (SDS) reducing buffer plus 10 mmol/L NaVO₃, 10 mmol/L ethylenediamine tetraacetic acid (EDTA), and 1 mmol/L PMSF, followed by boiling for 3 minutes. Platelet proteins were separated by 8% SDS-polycrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred onto Clear Blot Membrane-P (Atto, Tokyo, Japan). The membranes were blocked with 1% BSA in phosphate-buffered saline (PBS). After extensive washing with PBS containing 0.1% Tween 80, the immunoblots were incubated for 2 hours with the indicated antibody. Antibody binding was detected using peroxidase-conjugated goat antimouse IgG and visualized with ECL chemiluminescence reagents (Amersham, UK) and Konica X-ray film (JX 8 x 10; Konica Co, Tokyo, Japan).

**Isolation of cytoskeletal fractions and immunoprecipitation kinase assay.** After platelets were activated with wvF-botrocetin for the indicated period, reactions were terminated with an equal volume of ice-cold lysis buffer (2% Triton X-100, 100 mmol/L Tris/HCl, pH 7.5, 50 mmol/L NaCl, 5 mmol/L EDTA, 2 mmol/L vanadate, 1 mmol/L PMSF, and 100 μg/mL of leupeptin). The lysate was sonicated and centrifuged at 16,000g for 5 minutes. The pellet included Triton X-100-insoluble, cytoskeletal fractions. Finally, the Triton X-insoluble pellet was resuspended in Laemmli buffer and boiled for 3 minutes. Proteins present in this fraction were detected by Western blotting using MoAbs against various tyrosine kinases described above.

The supernatant was pre cleared with protein A Sepharose beads for 30 minutes at 4°C and then mixed with specific antityrosine kinase MoAb or anti-GPIb MoAb. The mixture was rotated for 2 hours at 4°C and, after the addition of protein A sepharose beads, further rotated for 2 hours. The sepharose beads were washed three times with lysis buffer. The sample was then split into two portions. One was used for immunoblotting as described elsewhere, and the other was processed further for an in vitro kinase assay. The in vitro kinase assay was performed as previously described. The beads were washed once with HEPES buffer (10 mmol/L HEPES/NaOH, 1 mmol/L vanadate, pH 8.0) and then incubated with 25 μL of kinase reaction buffer (300 mmol/L HEPES/NaOH, 15 mmol/L MnCl₂, 150 mmol/L MgCl₂, pH 8.0) with 10 μg of acid-treated enolase. The reaction was initiated by the addition of 2 μmol ATP (10 μCi of [γ-³²P]ATP). After 10 minutes at 20°C, reactions were stopped by the addition of Laemmli buffer and then subjected to boiling for 3 minutes. The proteins were separated under reducing conditions by 8% SDS-PAGE and transferred onto Clear Blot Membrane P. The membrane was treated with 1 mol/L KOH for 60 minutes, dried, and quantified with a BAS-2000 phosphor-image analyzer (Fuji Film, Tokyo, Japan).

**Phosphoamino acid analysis.** After the in vitro kinase reactions described above, the samples were applied on 8% SDS-PAGE. The phosphorylated proteins corresponding to phosphorylated enolase and the phosphorylated 60-kD protein were excised from polyacrylamide gels and homogenized in 100 mmol/L NH₄HCO₃, containing 0.2% SDS, 5% 2-mercaptoethanol, and 20 μL/μg of ribonuclease A. The homogenate was incubated for 5 minutes in boiling water and extracted overnight at 37°C. Proteins were precipitated with 20% trichloroacetic acid. After washing in ice-cold acetone and drying, the proteins were dissolved in 5.7 mol/L HCl and hydrolyzed for 1 hour at 110°C. Supernatants were concentrated by centrifugation, mixed with carrier phosphoamino acids, and analyzed by two-dimensional electrophoresis (pH 1.9 followed by pH 3.5). After autoradiography, the ³²P-labeled amino acids were identified by their comigration with the carrier proteins stained with ninhydrin.

**Measurement of p42/44 Erk activation.** Measurement of mitogen-activated protein (MAP) kinase activity in platelet activation was performed as previously described. Briefly, platelet reactions were stopped with an equal volume of SDS sample buffer (2% SDS, 5 mmol/L EDTA, 10 mmol/L Tris, 0.5 mmol/L PMSF, pH 7.3). The samples were boiled for 5 minutes and diluted 40-fold with Tris-buffered saline (20 mmol/L Tris, 137 mmol/L NaCl, 0.1% Tween 20, pH 7.6) containing 2 mg/mL of BSA, 1 mmol/L PMSF, and 1 mmol/L EDTA. The platelet lysates were pre cleared with sepharose beads for 1 hour and then incubated overnight with 4 μg of anti-
p42\textsuperscript{mosk} MoAb and with protein A-agarose CL-4B. The immunoprecipitates were resolved on 10% SDS-PAGE containing 50 μg/mL of myelin basic protein (MBP) in the gel. Proteins in gel were denatured with 6 M guanidine HCl and then renatured for 16 hours at 4°C with 50 mM Tris containing 5 mM L-2-mercaptoethanol and 0.04% Tween 20. For the kinase assay, the gels were incubated with kinase assay buffer (50 mM Tris, 5 mM MgCl\textsubscript{2}, 1 mM EDTA, 5 mM dithiothreitol, 50 μg/mL ATP, and 200 μCi of \( [\gamma^3P] \) ATP, pH 8.0) and with 50% trichloroacetic acid and 1% Na\textsubscript{2}H\textsubscript{4}P\textsubscript{2}O\textsubscript{7}. Gels were then dried and the radioactivity was measured with a BAS-2000 phosphor-image analyzer.

RESULTS

Platelet activation induced by the vWF-botrocetin interaction. Botrocetin, purified from the Bothrops jararaca snake venom, binds to GPIb,\textsuperscript{22} The combination of 10 μg/mL of vWF and botrocetin in the concentration range of 0.3 and 20 μg/mL induced platelet agglutination/aggregation independent of extracellular Ca\textsuperscript{2+}.\textsuperscript{14} Ristocetin, at concentrations ranging from 0.3 to 2.0 mg/mL, also induced platelet agglutination/aggregation in the presence of vWF.\textsuperscript{5,30} The magnitude of platelet aggregation induced by botrocetin, assessed as changes in light transmission, reached the maximum level at a concentration of 1 μg/mL, but it was less than that of 1 mg/mL of ristocetin. In experiments thereafter, the combination of 10 μg/mL of vWF and 3 μg/mL of botrocetin was used to activate platelets. Because vWF-botrocetin-mediated platelet agglutination/aggregation was accompanied by the appearance of the 64-kD tyrosine-phosphorylated protein,\textsuperscript{14} we then evaluated the changes in tyrosine kinase activity.

Tyrosine kinase activation induced by the vWF-botrocetin interaction. Botrocetin per se up to 20 μg/mL had no measurable effects on the tyrosine kinase activity, assessed as in vitro kinase assays of immunoprecipitated preparations of p72\textsuperscript{syk} or p60\textsuperscript{c-src}, whereas ristocetin, at concentrations of as low as 0.3 mg/mL, inhibited in vitro kinase assays of these tyrosine kinases (data not shown). Similarly, when platelets were activated by the combination of ristocetin and vWF, in vitro kinase assays of p72\textsuperscript{syk} and p60\textsuperscript{c-src} showed no kinase activity, and there were no changes related to platelet activation. These findings suggest that ristocetin nonspecifically interacts with tyrosine kinases, precluding the kinase activity measurement. Thus, in experiments thereafter, botrocetin, but not ristocetin, was used to facilitate the binding of vWF to GPIb.

When platelets were activated by the combination of 10 μg/mL of vWF and 3 μg/mL of botrocetin, lysed, and immunoprecipitated with the corresponding antibodies, there was no measurable increase in the tyrosine kinase activity of p60\textsuperscript{c-src}, p54/58\textsuperscript{fyn}, or p125\textsuperscript{FAK} (data not shown). On the other hand, vWF-botrocetin-stimulation induced a twofold to threefold increase in the level of p72\textsuperscript{syk} autophosphorylation, which peaked 15 to 60 seconds after stimulation and subsided to lower levels thereafter (Fig 1). Comitant with the change in p72\textsuperscript{syk} autophosphorylation, in vitro kinase assays showed that the tyrosine kinase activity, assessed by acid-treated protein-tyrosine phosphorylation (PTP) and p72\textsuperscript{syk} associated tyrosine kinase activity induced by vWF-botrocetin

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{p72\textsuperscript{syk}-associated tyrosine kinase activity induced by botrocetin-vWF. Platelets suspended in a buffer containing 1 mM Ca\textsuperscript{2+} were activated with 3 μg/mL of botrocetin and 10 μg/mL of vWF for the indicated time intervals. Reactions were terminated with lysis buffer, and p72\textsuperscript{syk} was isolated by immunoprecipitation with anti-p72\textsuperscript{syk} MoAb. Immunoprecipitates were directly subjected to Western blotting using the antiphosphotyrosine MoAb, 4G10. The arrow represents the band presumably derived from IgG heavy chains. The data are representative of three experiments.}
\end{figure}
Fig 2. Association of p60<sup>crk</sup> with p72<sup>syk</sup> induced by botrocetin-vWF. Platelets were activated with 3 
μg/mL of botrocetin and 10 
μg/mL of vWF, and 
p72<sup>syk</sup>-associated proteins were isolated by immuno-
precipitation with anti-p72<sup>syk</sup> MoAb. The sample was 
applied to SDS-PAGE and Western blotting using 
anti-p60<sup>crk</sup> MoAb. The data are representative of 
three experiments.

Fig 3. Effects of jararaca GPIIb-BP on PTP of whole 
cell lysates (A) and p72<sup>syk</sup> activation (B) induced by 
botrocetin-vWF. Platelets were incubated with or 
without 10 
μg/mL of jararaca GPIIb-BP for 5 minutes 
and then activated with 3 
μg/mL of botrocetin and 
10 
μg/mL of vWF for the indicated time intervals. 
For PTP analysis, reactions were terminated with 
Laemmli SDS buffer, and samples were Western-
blotted using antiphosphotyrosine MoAb, 4G10. For 
analysis of p72<sup>syk</sup> autophosphorylation, reactions 
were terminated by adding lysis buffer. p72<sup>syk</sup> was 
immunoprecipitated with anti-p72<sup>syk</sup> MoAb, and the 
sample was Western-blotted using antiphosphotyro-
sine MoAb, 4G10. (A) PTP in whole cell lysates. The 
arrowhead indicates 64-kD PTP. (B) p72<sup>syk</sup> autophos-
phorylation. The arrowhead represents the band pre-
sumably from IgG heavy chains. The data are repre-
sentative of three experiments.
platelet activation uses an Shc-related signal transduction pathway distinct from that of thrombin activation.

Failure of vWF-GPIb to activate MAP kinase. The sequential kinase cascade leading to the activation of MAP kinase lies downstream of Shc, Ras, and Sos. Platelets contain two isoforms of MAP kinase, 42\textsuperscript{mkk} and 44\textsuperscript{mkk}, and MAP kinase is activated in collagen- or thrombin-stimulated platelets.\textsuperscript{28,34} Because Shc is tyrosine-phosphorylated by the vWF-GPIb interaction, we investigated MAP kinase activation stimulated by botrocetin-vWF. There was little p42/44\textsuperscript{mkk} activation in vWF-GPIb-stimulated platelets, whereas p42/44\textsuperscript{mkk} was markedly activated in thrombin-induced platelet activation (Fig 6), suggesting that p42/44\textsuperscript{mkk} activation does not contribute to the vWF-GPIb-induced signal transduction pathways.

Association of p60\textsuperscript{src} and p54/58\textsuperscript{lyn} with Triton X-100-insoluble cytoskeletal fractions in platelets activated by vWF-botrocetin. Tyrosine kinases such as p60\textsuperscript{src} and p72\textsuperscript{syk} translocate to cytoskeletons upon platelet activation induced by various agonists.\textsuperscript{35,37} We therefore assessed the translocation of tyrosine kinases, p72\textsuperscript{syk}, p60\textsuperscript{src}, and p54/58\textsuperscript{lyn}, to cytoskeletons during platelet activation induced by vWF-botrocetin. The addition of vWF or botrocetin alone did not cause the translocation of p72\textsuperscript{syk}, p60\textsuperscript{src}, and p54/58\textsuperscript{lyn} to cytoskeletal fractions (Fig 7). VWF-botrocetin stimulation induced an 8.3-fold (n = 3) and a 9.2-fold (n = 3) increase of p60\textsuperscript{src} and of p54/58\textsuperscript{lyn}, respectively, associated with Triton X-100-insoluble cytoskeletal fractions, as compared with the resting state (Fig 7). Translocation of p60\textsuperscript{src} and p54/58\textsuperscript{lyn} to cytoskeletal fractions was delayed and diminished by 10 \(\mu\)g/mL of jararaca GPIb-BP (Fig 8A and B), but was not abolished by 200 \(\mu\)mol/L GRGDS peptide plus 1 mmol/L EGTA (Fig 8C and D). These findings suggest that translocation of tyrosine kinases to cytoskeletons induced by botrocetin-vWF is specifically mediated through the interaction between GPIb and vWF. In contrast, p72\textsuperscript{syk} translocation to the Triton-X-insoluble cytoskeletons was not detectable (Fig 7).

Association of tyrosine kinase(s) with GPIb. Signal transduction pathways involving some membrane glycoproteins are mediated by the association between receptors and tyrosine kinases.\textsuperscript{38-40} We therefore sought to determine whether GPIb binds to tyrosine kinases during platelet activation induced by the combination of vWF and botrocetin. First, we used two anti-GPIb MoAbs, GUR83-35 and NNKY5-5, that inhibit vWF binding to GPIb for GPIb immunoprecipitation and found no tyrosine kinase activity associated with GPIb after platelet activation (data not shown). We then used two anti-GPIb MoAbs, WGA-3 and GS-70, both of which bind to GPIb but do not interfere with the binding of vWF to GPIb. When GPIb was immunoprecipitated with these nonfunctional anti-GPIb MoAbs after plate-
Fig 6. Measurement of p42mapk and p44mapk induced by botrocetin-vWF. Platelets (10^9/mL) were stimulated with 1 U/mL of thrombin or 3 μg/mL of botrocetin and 10 μg/mL of vWF for the indicated time intervals, and reactions were terminated with an equal volume of SDS sample buffer. Samples were boiled for 5 minutes and diluted 40-fold with Tris-buffered saline. p42mapk was immunoprecipitated using anti-p42mapk MoAb and the immunoprecipitates were subjected to electrophoresis on 10% SDS-PAGE gels containing 0.5 mg/mL of MBP. The MAP kinase in gel was then renatured, and the gels were incubated with the kinase assay buffer containing [γ-32P]ATP. The autoradiograph shows the band of renatured p42mapk activity. The data are representative of three experiments.

As platelets were activated by the combination of vWF and botrocetin, in vitro kinase assays of the GPIb-immunoprecipitate showed that the phosphorylated levels of enolase, added as substrate, and an unidentified protein of approximately 60 kD were elevated (Fig 9). The kinase activity reached its peak 15 seconds after activation and gradually decreased after 1 minute. GPIb itself was not phosphorylated. These findings suggest that GPIb associates with protein kinase(s) upon vWF-botrocetin–platelet activation. We then asked whether the elevated kinase activity associated with GPIb was a tyrosine- or serine/threonine-kinase. Phosphoamino acid analysis of 32P-labeled enolase and the 60-kD protein showed that only the tyrosine residues were phosphorylated, suggesting that tyrosine kinase activity associated with GPIb upon the vWF-GPIb interaction (Fig 10). Western blotting of immunoprecipitated GPIb with antiphosphotyrosine MoAb showed no band of tyrosine phosphorylation, suggesting that the tyrosine kinase itself is not autophosphorylated (data not shown). Western blotting with anti-p72^syk, anti-p54/58^lyn, anti-p60^src, anti-p62 yes, or anti-p59^fyn MoAbs showed no cross-reactivity, and the tyrosine kinase associated with GPIb remains to be identified.

DISCUSSION

Changes in protein tyrosine phosphorylation of cell lysates and translocation of p60^src occur upon GPIb-mediated platelet activation. In the present study, we have confirmed these findings and further demonstrated that several intracellular changes related to tyrosine kinases also take place in botrocetin-vWF–induced platelet activation. These include tyrosine phosphorylation of Shc (an adaptor protein); translocation of p60^src and p54/58^lyn, but not of p72^syk to cytoskeletal fractions; p72^syk activation; and the association between p72^syk and p60^src.

Among a number of tyrosine kinases present in platelets, three tyrosine kinases, p72^syk, p60^src, and p125^fak, are known to increase the activity upon platelet activation induced by various agonists. Based on the level of p72^syk autophosphorylation and in vitro kinase assays, we found that botrocetin-vWF promoted an increase in the level of p72^syk activity, whereas changes in p60^src or p125^fak activity were not observed. Compared with collagen or thrombin stimulation, which causes a 10-fold increase in the p72^syk activity, the effect of botrocetin-vWF was limited, amounting to a twofold to threefold increase at most. Jara-raca GPIb-binding protein, which inhibits the binding of vWF to GPIb, abrogated the increase in p72^syk activity and the translocation of p60^src and p54/58^lyn to cytoskeletal fractions induced by botrocetin-vWF, suggesting that p72^syk activation is caused specifically by the GPIb-vWF interaction. Furthermore, those tyrosine kinase-related events induced by vWF-botrocetin appear to occur independently of vWF and fibrinogen binding to GPIIb/IIIa because the responses

Fig 7. Cytoskeletal association of p60^src, p54/58^lyn, and p72^syk induced by botrocetin-vWF. Platelets were activated with 3 μg/mL of botrocetin and 10 μg/mL of vWF for the indicated time intervals. Reactions were then stopped with lysis buffer, and Triton-X–insoluble fractions were harvested by centrifugation at 16,000 g for 5 minutes. The pellets were solubilized with Laemmli buffer. Cytoskeletal association of tyrosine kinases is detected by Western blotting using anti-p60^src (A), anti-p54/58^lyn (B), and anti-p72^syk (C) MoAbs. w, whole cell lysates.
Fig 8. Effects of jararaca GPIb-BP or GRGDS peptide plus EGTA on the cytoskeletal association of p60c-src and p54/58lyn induced by botrocetin-vWF. Platelets were incubated with or without 10 μg/mL of jararaca GPIb-BP (A and B) or with or without 200 μmol/L GRGDS peptide plus 1 mmol/L EGTA (instead of Ca2⁺) (C and D) for 5 minutes and then activated with 3 μg/mL of botrocetin and 10 μg/mL of vWF for the indicated time intervals. Cytoskeletal fractions were harvested as described in the legend for Fig 7. Immunoblot analysis of cytoskeletal fractions were performed with anti-p60c-src (A and C) and anti-p54/58lyn (B and D) MoAbs.

were not affected by GRGDS plus EGTA. This finding is consistent with the report by Jackson et al.¹⁷ that pretreatment of RGDS did not alter the vWF-stimulated activation. To the best of our knowledge, our report is the first to show changes in tyrosine kinase activity mediated by the GPIb-vWF interaction. Our success may be attributed to the use of botrocetin, instead of ristocetin, for facilitating the association between GPIb and vWF. Ristocetin, a glycopeptide antibiotic rich in cationic charges, appears to interfere with the p72syk activity, rendering the detection of its changes impossible. We have also found that p72syk associates with p60c-src upon botrocetin-vWF stimulation. The interaction between p72syk and p60c-src has been reported with Fc receptor-mediated platelet activation,⁴² and we have recently found that the SH2 domain of p72syk is responsible for their association (unpublished data). It is likely that tyrosine phosphorylated p60c-src is associated with p72syk. However, as discussed above, there is no measurable increase in the tyrosine kinase activity of p60c-src. It may be that only a small percentage of the total p60c-src is activated, which then becomes associated with p72syk.

Shc, a member of the adaptor protein family, does not possess tyrosine kinase activity per se, but does act as an adaptor to facilitate the binding of different signaling molecules.³¹-³³ The presence of the SH2 domain that binds to phosphorylated tyrosine residues appears to be essential for this function, and Shc itself can be tyrosine-phosphorylated to facilitate its binding to the SH2 domain of other molecules.³²,³³ In platelets, Shc phosphorylation and its association with Grb2 occurs upon thrombopoietin or thrombin stimulation.⁴⁴ Shc tyrosine phosphorylation and its association with Grb2 is known to activate MAP kinase that lies downstream. We found that Shc is tyrosine-phosphorylated by vWF-botrocetin activation, but we were not able to identify its association with other molecules including Grb2. Furthermore, vWF-botrocetin did not induce MAP kinase activation, whereas thrombin did activate MAP kinase, as assessed by renatured kinase assays.²⁷ It is likely that the Shc-related signaling pathway in vWF-botrocetin activation is distinct from that of thrombin.

Upon platelet activation, a number of proteins, including p60c-src, translocate to the Triton-X- insoluble cytoskeletal fraction.⁴⁵,⁴⁶ Although the precise role of cytoskeletal association of tyrosine kinases remains largely unknown, it may contribute to stabilizing platelet aggregates or to inducing clot retraction.⁴⁷ We have recently found that p54/58lyn and p60c-src, but not p72syk, translocate to the cytoskeletal fraction upon platelet activation induced by collagen or thrombin.

Fig 9. GPIb-associated kinase activity induced by botrocetin-vWF. Platelets (10⁹ cells/mL) suspended in a buffer containing 1 mmol/L Ca²⁺ were activated with 3 μg/mL of botrocetin and 10 μg/mL of vWF for the indicated time intervals. Reactions were then terminated with lysis buffer, and GPIb was isolated by immunoprecipitation with anti-GPIb MoAbs, WGA3. In vitro kinase assays were performed using enolase as exogenous substrate. The proteins were separated under reducing conditions by 8% SDS-PAGE and quantified with a BAS 2000 phosphorimager. The arrow represents the band presumably derived from IgG heavy chains. The data are representative of three experiments.
receptor activation peptides, whereas thrombin induced p72\textsuperscript{syk} translocation to cytoskeletons. In the present study, we have shown that vWF-botrocetin stimulation also induced the cytoskeletal association of p60\textsuperscript{src} and p54/58\textsuperscript{fyn}, but not that of p72\textsuperscript{syk}. These findings suggest that there is a qualitative difference in the translocation of tyrosine kinases to the cytoskeleton, between vWF-GPIb- induced and thrombin-induced platelet activation. Jararaca GPIb-BP delayed but did not eliminate the translocation of p60\textsuperscript{src} and p54/58\textsuperscript{fyn} to cytoskeletal fractions (Fig 8A and B). We assume that the blockade of botrocetin-induced vWF binding to GPIb by jararaca GPIb-BP may not be complete and that some signaling induced by vWF-GPIb, although attenuated, remained in effect, because the binding of jararaca GPIb-BP and vWF is competitive.

The findings thus far have clearly shown the involvement of tyrosine kinases in the signal transduction pathway in botrocetin-vWF activation, whereas their significance, mutual interactions, and place in the sequential propagation of activation signals remain largely unknown. What signal lies most proximal to the GPIb-vWF interaction? In platelets as well as in other cells, a number of membrane signaling molecules appear to associate with tyrosine kinases upon activation. In B cells, the B-cell antigen receptor colocalizes with p54/58\textsuperscript{fyn}. In Fc receptor-mediated activation, the association between the Fc receptor and tyrosine kinases appears to be the initial step of activation.\textsuperscript{40} In the same line of reasoning, GPIb may associate with a kinase activity upon botrocetin-vWF activation. Thus, we sought to address this issue by evaluating the kinase activity coprecipitated with GPIb.

We first used several anti-GPIb MoAbs that inhibit ristocetin/botrocetin-induced platelet agglutination/aggregation for immunoprecipitation GPIb, only to find that no kinase activity associated with GPIb upon botrocetin-vWF activation. However, when we immunoprecipitated GPIb with two nonfunctional anti-GPIb MoAbs, the GPIb-linked kinase activity was increased upon platelet activation. Phosphoamino acid analysis showed that the kinase activity was due to a tyrosine kinase associated with GPIb. Under our immunoprecipitation conditions, at least GPIb and GPIIX retain a complex form. Accordingly, we cannot draw a conclusion on which component of the GPIb-IX and V complex is associated with the tyrosine kinase activity observed in this study. The tyrosine kinase appeared not to be autophosphorylated and was not identical with p54/58\textsuperscript{fyn}, p60\textsuperscript{src}, p59\textsuperscript{fyn}, p72\textsuperscript{syk}, or p125\textsuperscript{FAK} as assessed by Western blotting. However, the failure to detect phosphotyrosine residues by Western blotting may be due to a low sensitivity of this method for evaluating tyrosine kinase coassociation in the GPIb immunoprecipitate. Hence, it may be inappropriate to draw conclusions regarding whether the tyrosine kinase associated with GPIb is autophosphorylated or whether it corresponds to known platelet tyrosine kinases. The increase in the tyrosine kinase activity associated with GPIb occurred before translocation of tyrosine kinases to the cytoskeleton or Shc phosphorylation. These results imply that the unidentifed tyrosine kinase plays an essential role in the proximal step of the signal transduction pathway in vWF-GPIb-induced platelet interactions.

In conclusion, we show that the vWF-GPIb interaction induces several tyrosine kinase-related intracellular changes, including p72\textsuperscript{syk} activation, its association with p60\textsuperscript{src}, Shc tyrosine phosphorylation, and cytoskeletal association of p60\textsuperscript{src} and p54/58\textsuperscript{fyn}. An unidentifed tyrosine kinase activity associated with GPIb appears to be one of the earliest intracellular signals. However, more work is necessary to determine whether it binds directly or indirectly to GPIb.

ACKNOWLEDGMENT

The authors are grateful to Dr N. Yamamoto and Dr S. Nomura for providing us with valuable anti-GPIb MoAbs. We are also indebted to Dr G. Kato (Yamanashi Medical University, Yamanashi, Japan) for his valuable advice.

REFERENCES


45. Horvath AR, Muzbek L, Kellie S: Translocation of pp60\textsuperscript{Src} to the cytoskeleton during platelet aggregation. EMBO J 11:855, 1992


47. Schoenwaelder SM, Jackson SP, Yuan Y, Teasdale MS, Salem HH, Mitchell CA: Tyrosine kinases regulate the cytoskeletal attachment of integrin alphaIIb beta3 (platelet glycoprotein GPIIb/IIIa) and the cellular retraction of fibrin polymers. J Biol Chem 269:32479, 1994


Glycoprotein Ib-von Willebrand Factor Interactions Activate Tyrosine Kinases in Human Platelets

Naoki Asazuma, Yukio Ozaki, Kaneo Satoh, Yutaka Yatomi, Makoto Handa, Yoshihiro Fujimura, Shuji Miura and Shoji Kume